NDAORALTABLET1 Generic Approved
Approved
Nov 2004
Lifecycle
LOE Approaching
Competitive Pressure
45/100
Clinical Trials
20
Data completeness
3/8 — Basic
Drug data last refreshed 3h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
VESICARE (solifenacin succinate) is an oral anticholinergic small molecule approved in 2004 for overactive bladder (OAB) treatment. It reduces urinary frequency, urgency, and incontinence by relaxing bladder smooth muscle. The drug is indicated for patients with symptoms of OAB including urge incontinence, urgency, and urinary frequency.
$6MPart D
LOE ApproachingWith LOE approaching and modest Part D spending of $6M, the brand team is likely focused on lifecycle extension and managed decline strategies rather than aggressive growth initiatives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (20)
Bioequivalence Study of Solifenacin Succinate & Mirabegron From Mirfenacin MR 5/50 mg Extended Release Tablets (Hikma Pharma, Egypt) Versus Vesicare 5 mg FCT & Betmiga 50 mg Prolonged-Release Tablets (Astellas Pharma Europe B.V, the Netherlands / Astellas Pharma Europe B.V, the Netherlands)
Started May 2022
30 enrolled
Healthy
A Multinational Study Comparing the Long-term Efficacy and Safety of Two Medicines, Solifenacin Succinate and Mirabegron Taken Together, or Separately, in Subjects With Symptoms of Overactive Bladder
Started Mar 2014
1,829 enrolled
Urinary Bladder OveractiveOveractive BladderUrgency Incontinence+1 more
This Was a Multinational Study Comparing the Efficacy and Safety of Two Medicines , Solifenacin Succinate and Mirabegron Taken Together, or Separately, or a Mock Treatment (Placebo) in Subjects With Symptoms of Overactive Bladder
Started Nov 2013
3,527 enrolled
Urinary Bladder OveractiveUrinary Bladder Diseases\Urologic DiseasesOveractive Bladder+1 more
The Efficacy of Solifenacin Succinate as Adjuvant Therapy for Urinary Tract Infection in Females
Started Apr 2013
126 enrolled
Urinary Tract Infection
VESIcare For Improving OAB Symptoms in Patients Undergoing IGRT of the Prostate
Started Feb 2013
8 enrolled
Over-Active Bladder
Worked on VESICARE at Astellas? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.